TG Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
TG Therapeutics has a total shareholder equity of $160.1M and total debt of $101.6M, which brings its debt-to-equity ratio to 63.5%. Its total assets and total liabilities are $373.3M and $213.2M respectively. TG Therapeutics's EBIT is $48.4M making its interest coverage ratio 4. It has cash and short-term investments of $209.8M.
Key information
63.5%
Debt to equity ratio
US$101.65m
Debt
| Interest coverage ratio | 4x |
| Cash | US$209.79m |
| Equity | US$160.11m |
| Total liabilities | US$213.21m |
| Total assets | US$373.32m |
Recent financial health updates
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Financial Position Analysis
Short Term Liabilities: TGTX's short term assets ($360.6M) exceed its short term liabilities ($99.7M).
Long Term Liabilities: TGTX's short term assets ($360.6M) exceed its long term liabilities ($113.5M).
Debt to Equity History and Analysis
Debt Level: TGTX has more cash than its total debt.
Reducing Debt: TGTX's debt to equity ratio has reduced from 147.6% to 63.5% over the past 5 years.
Debt Coverage: TGTX's debt is not well covered by operating cash flow (20%).
Interest Coverage: TGTX's interest payments on its debt are well covered by EBIT (4x coverage).